Efficacité en pratique clinique courante des incrétino-mimétiques dans le traitement du diabète de type 2 : résultats d'une enquête nationale rétrospective au Royaume-Uni

This study retrospectively assessed, over 12 months, the clinical effectiveness of incretin based therapies (glucagon-like peptide-1 receptor agonists [GLP1-ra]: liraglutide and exenatide; dipeptidylpeptidase IV inhibitors [DPP4-i]) initiated according to the National Institute for Health & Clinical Excellence (NICE) recommendations, among type 2 diabetes patients in Wales, UK. HbA1c level reduction was significantly greater with liraglutide vs. exenatide or DPP4-i. Moreover, weight loss was significantly increased for both liraglutide and exenatide vs. DPP4-i. Patient preference between GLP1-ra and DPP4-i was also studied in a separate prospective study.